Skip to main content
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
20.96
-0.68 (-3.14%)
At close: Feb 27, 2026, 4:00 PM EST
20.80
-0.16 (-0.76%)
After-hours: Feb 27, 2026, 7:55 PM EST

Apellis Pharmaceuticals Revenue

In the year 2025, Apellis Pharmaceuticals had annual revenue of $1.00B with 28.46% growth. Apellis Pharmaceuticals had revenue of $199.91M in the quarter ending December 31, 2025, a decrease of -5.94%.

Revenue (ttm)
$1.00B
Revenue Growth
+28.46%
P/S Ratio
2.67
Revenue / Employee
$1,358,298
Employees
739
Market Cap
2.68B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.00B222.42M28.46%
Dec 31, 2024781.37M384.78M97.02%
Dec 31, 2023396.59M321.17M425.83%
Dec 31, 202275.42M8.86M13.31%
Dec 31, 202166.56M-184.08M-73.44%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Catalyst Pharmaceuticals 588.99M
Travere Therapeutics 490.73M
Arcus Biosciences 247.00M
IDEAYA Biosciences 218.71M
Beam Therapeutics 139.74M
Viridian Therapeutics 70.85M
Liquidia 69.22M
Wave Life Sciences 42.73M
Revenue Rankings

APLS News

More News